Setting

North America Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity

Published: 30 Dec 2021 | Report Code: 10248306 | Pages: 102

North America monoclonal antibodies market is projected to grow by 10.4% annually in the forecast period and reach $133.4 billion by 2030, driven by the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies. Highlighted with 24 tables and 48 figures, this 102-page report “North America Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country. Based on Source, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Human • Humanized • Chimeric • Murine Based on Category, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Branded mAbs • Biosimilar mAbs Based on Production Type, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • In Vitro Production • In Vivo Production Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Cancer o Breast Cancer o Colorectal Cancer o Lung Cancer o Ovarian Cancer o Other Cancer Types • Autoimmune Diseases • Inflammatory Diseases • Infectious Diseases • Other Applications By End User, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Hospitals • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories AbbVie, Inc. Amgen Inc. AstraZeneca plc Bayer AG Bristol-Myers Squibb Company Eli Lilly F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Johnson & Johnson Merck & Co., Inc. Mylan N.V Norvatis AG Pfizer Sanofi S.A. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	20
2.1.2 Impact of COVID-19 on the Market	22
2.2 Major Growth Drivers	24
2.3 Market Restraints and Challenges	29
2.4 Emerging Opportunities and Market Trends	32
2.5 Porter’s Fiver Forces Analysis	36
3 Segmentation of North America Market by Source	40
3.1 Market Overview by Source	40
3.2 Human	42
3.3 Humanized	43
3.4 Chimeric	44
3.5 Murine	45
4 Segmentation of North America Market by Category	46
4.1 Market Overview by Category	46
4.2 Branded mAbs	48
4.3 Biosimilar mAbs	49
5 Segmentation of North America Market by Production Type	50
5.1 Market Overview by Production Type	50
5.2 In Vitro Production	52
5.3 In Vivo Production	53
6 Segmentation of North America Market by Application	54
6.1 Market Overview by Application	54
6.2 Cancer	56
6.2.1 Breast Cancer	58
6.2.2 Colorectal Cancer	59
6.2.3 Lung Cancer	60
6.2.4 Ovarian Cancer	61
6.2.5 Other Cancer Types	62
6.3 Autoimmune Diseases	63
6.4 Inflammatory Diseases	64
6.5 Infectious Diseases	65
6.6 Other Applications	66
7 Segmentation of North America Market by End User	67
7.1 Market Overview by End User	67
7.2 Hospitals	69
7.3 Research Institutes	70
7.4 Other End Users	71
8 North America Market 2019-2030 by Country	72
8.1 Overview of North America Market	72
8.2 U.S.	75
8.3 Canada	78
8.4 Mexico	80
9 Competitive Landscape	82
9.1 Overview of Key Vendors	82
9.2 New Product Launch, Partnership, Investment, and M&A	85
9.3 Company Profiles	86
Abbott Laboratories	86
AbbVie, Inc.	88
Amgen Inc.	89
AstraZeneca plc	90
Bayer AG	91
Bristol-Myers Squibb Company	92
Eli Lilly	93
F. Hoffmann-La Roche Ltd.	94
GlaxoSmithKline Plc	95
Johnson & Johnson	96
Merck & Co., Inc.	97
Mylan N.V	98
Norvatis AG	99
Pfizer	100
Sanofi S.A.	101
RELATED REPORTS	102
List Of Tables:


Table 1.  Snapshot of North America Monoclonal Antibodies Market in Balanced Perspective, 2019-2030	17
Table 2. Growth Rate of World GDP, 2020-2022	21
Table 3. World Health Spending by Region, $ bn, 2013-2020	28
Table 4.  Main Product Trends and Market Opportunities in North America Monoclonal Antibodies Market	32
Table 5. North America Monoclonal Antibodies Market by Source, 2019-2030, $ bn	40
Table 6. North America Monoclonal Antibodies Market by Category, 2019-2030, $ bn	46
Table 7. North America Monoclonal Antibodies Market by Production Type, 2019-2030, $ bn	50
Table 8. North America Monoclonal Antibodies Market by Application, 2019-2030, $ bn	54
Table 9. North America Monoclonal Antibodies Market: Cancer Therapy by Type, 2019-2030, $ bn	57
Table 10. North America Monoclonal Antibodies Market by End User, 2019-2030, $ bn	67
Table 11. North America Monoclonal Antibodies Market by Country, 2019-2030, $ bn	73
Table 12. U.S. Monoclonal Antibodies Market by Source, 2019-2030, $ bn	77
Table 13. U.S. Monoclonal Antibodies Market by Application, 2019-2030, $ bn	77
Table 14. U.S. Monoclonal Antibodies Market by End User, 2019-2030, $ bn	77
Table 15. Canada Monoclonal Antibodies Market by Source, 2019-2030, $ bn	79
Table 16. Canada Monoclonal Antibodies Market by Application, 2019-2030, $ bn	79
Table 17. Canada Monoclonal Antibodies Market by End User, 2019-2030, $ bn	79
Table 18. Mexico Monoclonal Antibodies Market by Source, 2019-2030, $ bn	81
Table 19. Mexico Monoclonal Antibodies Market by Application, 2019-2030, $ bn	81
Table 20. Mexico Monoclonal Antibodies Market by End User, 2019-2030, $ bn	81
Table 21. Abbott Laboratories: Company Snapshot	86
Table 22. Abbott Laboratories: Business Segmentation	86
Table 23. Abbott Laboratories: Product Portfolio	87
Table 24. Abbott Laboratories: Revenue, 2018-2020, $ bn	87
List of Figures:


Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	16
Figure 4. North America Monoclonal Antibodies Market, 2019-2030, $ bn	19
Figure 5. Impact of COVID-19 on Business	22
Figure 6. Primary Drivers and Impact Factors of North America Monoclonal Antibodies Market	24
Figure 7.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	27
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060	27
Figure 9. Primary Restraints and Impact Factors of North America Monoclonal Antibodies Market	29
Figure 10. Investment Opportunity Analysis	33
Figure 11. Porter’s Fiver Forces Analysis of North America Monoclonal Antibodies Market	36
Figure 12. Breakdown of North America Monoclonal Antibodies Market by Source, 2019-2030, % of Revenue	41
Figure 13. North America Addressable Market Cap in 2021-2030 by Source, Value ($ bn) and Share (%)	41
Figure 14. North America Monoclonal Antibodies Market by Source: Human, 2019-2030, $ bn	42
Figure 15. North America Monoclonal Antibodies Market by Source: Humanized, 2019-2030, $ bn	43
Figure 16. North America Monoclonal Antibodies Market by Source: Chimeric, 2019-2030, $ bn	44
Figure 17. North America Monoclonal Antibodies Market by Source: Murine, 2019-2030, $ bn	45
Figure 18. Breakdown of North America Monoclonal Antibodies Market by Category, 2019-2030, % of Sales Revenue	47
Figure 19. North America Addressable Market Cap in 2021-2030 by Category, Value ($ bn) and Share (%)	47
Figure 20. North America Monoclonal Antibodies Market by Category: Branded mAbs, 2019-2030, $ bn	48
Figure 21. North America Monoclonal Antibodies Market by Category: Biosimilar mAbs, 2019-2030, $ bn	49
Figure 22. Breakdown of North America Monoclonal Antibodies Market by Production Type, 2019-2030, % of Sales Revenue	51
Figure 23. North America Addressable Market Cap in 2021-2030 by Production Type, Value ($ bn) and Share (%)	51
Figure 24. North America Monoclonal Antibodies Market by Production Type: In Vitro Production, 2019-2030, $ bn	52
Figure 25. North America Monoclonal Antibodies Market by Production Type: In Vivo Production, 2019-2030, $ bn	53
Figure 26. Breakdown of North America Monoclonal Antibodies Market by Application, 2019-2030, % of Revenue	55
Figure 27. North America Addressable Market Cap in 2021-2030 by Application, Value ($ bn) and Share (%)	55
Figure 28. North America Monoclonal Antibodies Market by Application: Cancer, 2019-2030, $ bn	56
Figure 29. North America Monoclonal Antibodies Market by Cancer Type: Breast Cancer, 2019-2030, $ bn	58
Figure 30. North America Monoclonal Antibodies Market by Cancer Type: Colorectal Cancer, 2019-2030, $ bn	59
Figure 31. North America Monoclonal Antibodies Market by Cancer Type: Lung Cancer, 2019-2030, $ bn	60
Figure 32. North America Monoclonal Antibodies Market by Cancer Type: Ovarian Cancer, 2019-2030, $ bn	61
Figure 33. North America Monoclonal Antibodies Market by Cancer Type: Other Cancer Types, 2019-2030, $ bn	62
Figure 34. North America Monoclonal Antibodies Market by Application: Autoimmune Diseases, 2019-2030, $ bn	63
Figure 35. North America Monoclonal Antibodies Market by Application: Inflammatory Diseases, 2019-2030, $ bn	64
Figure 36. North America Monoclonal Antibodies Market by Application: Infectious Diseases, 2019-2030, $ bn	65
Figure 37. North America Monoclonal Antibodies Market by Application: Other Applications, 2019-2030, $ bn	66
Figure 38. Breakdown of North America Monoclonal Antibodies Market by End User, 2019-2030, % of Revenue	68
Figure 39. North America Addressable Market Cap in 2021-2030 by End User, Value ($ bn) and Share (%)	68
Figure 40. North America Monoclonal Antibodies Market by End User: Hospitals, 2019-2030, $ bn	69
Figure 41. North America Monoclonal Antibodies Market by End User: Research Institutes, 2019-2030, $ bn	70
Figure 42. North America Monoclonal Antibodies Market by End User: Other End Users, 2019-2030, $ bn	71
Figure 43. Breakdown of North America Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue	73
Figure 44. Contribution to North America 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%)	74
Figure 45. U.S. Monoclonal Antibodies Market, 2019-2030, $ bn	76
Figure 46. Canada Monoclonal Antibodies Market, 2019-2030, $ bn	78
Figure 47.  Monoclonal Antibodies Market in Mexico, 2019-2030, $ bn	80
Figure 48. Growth Stage of North America Monoclonal Antibodies Industry over the Forecast Period	82
Key Players (this may not be a complete list and extra companies can be added upon request): 
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)